The Combination of Bortezomib with Cyclophosphamide, Epirubicin, Etoposide and Prednisone (BCHEP) Regimen As First-Line Treatment for Untreated Patients with Peripheral T Cell Lymphoma: A Prospective, Single Arm, Phase II Study

doi:10.1182/blood-2021-149541

	The Combination of Bortezomib with Cyclophosphamide, Epirubicin, Etoposide and Prednisone (BCHEP) Regimen As First-Line Treatment for Untreated Patients with Peripheral T Cell Lymphoma: A Prospective, Single Arm, Phase II Study
	Yang, Haiyan 1,2; Li, Cong 1,2
刊名	BLOOD
	2021-11-23
卷号	138
ISSN号	0006-4971
DOI	10.1182/blood-2021-149541
WOS研究方向	Hematology
语种	英语
出版者	AMER SOC HEMATOLOGY
WOS记录号	WOS:000736413901211
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/131938]
专题	中国科学院合肥物质科学研究院
作者单位	1.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Yang, Haiyan,Li, Cong. The Combination of Bortezomib with Cyclophosphamide, Epirubicin, Etoposide and Prednisone (BCHEP) Regimen As First-Line Treatment for Untreated Patients with Peripheral T Cell Lymphoma: A Prospective, Single Arm, Phase II Study[J]. BLOOD,2021,138.
APA	Yang, Haiyan,&Li, Cong.(2021).The Combination of Bortezomib with Cyclophosphamide, Epirubicin, Etoposide and Prednisone (BCHEP) Regimen As First-Line Treatment for Untreated Patients with Peripheral T Cell Lymphoma: A Prospective, Single Arm, Phase II Study.BLOOD,138.
MLA	Yang, Haiyan,et al."The Combination of Bortezomib with Cyclophosphamide, Epirubicin, Etoposide and Prednisone (BCHEP) Regimen As First-Line Treatment for Untreated Patients with Peripheral T Cell Lymphoma: A Prospective, Single Arm, Phase II Study".BLOOD 138(2021).